Gamma secretase

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 7: Line 7:
== Background ==
== Background ==
-
γ-secretase belongs to the family of intramembrane-cleaving proteases (i-CLiPs), which includes the presenilin family of '''aspartyl proteases''', the zinc metalloprotease, site-2 protease family, and the rhomboid family of serine proteases. All i-CLiPs enzymatically cleave their substrates within the plane of the lipid bilayer in a process termed regulated intramembrane proteolysis. γ-secretase is mainly involved in intramembranous proteolysis of type I membrane proteins. It cleaves numerous functionally important proteins, such as Notch, E-cadherin, ErbB4, CD44, tyrosinase, TREM2 and Alcadein, suggesting the participation of γ-secretase in a vast range of biological activities. The best-studied γ-secretase substrates are APP for its roles in Alzheimer’s Disease, and Notch for its importance in development and cell fate determination.<ref name= "zhang">DOI:10.3389/fncel.2014.00427</ref>
+
γ-secretase falls under the family of intramembrane-cleaving proteases (i-CLiPs); this includes: the presenilin family of '''aspartyl proteases''', zinc metalloprotease, site-2 protease family, and rhomboid family of serine proteases. All i-CLiPs enzymatically cleave their substrates within the plane of the lipid bilayer in a process termed regulated intramembrane proteolysis. A large function of γ-secretase is its involvement in intramembranous proteolysis of type I membrane proteins. It cleaves numerous functionally important proteins, such as Notch, E-cadherin, ErbB4, CD44, tyrosinase, TREM2 and Alcadein, suggesting the participation of γ-secretase in a vast range of biological activities. The best-studied γ-secretase substrates are APP for its roles in Alzheimer’s Disease, and Notch for its importance in development and cell fate determination.<ref name= "zhang">DOI:10.3389/fncel.2014.00427</ref>
== Structure of Gamma Secretase Complex ==
== Structure of Gamma Secretase Complex ==
Line 23: Line 23:
On the cell surface, amyloid precursor protein (APP) can be proteolyzed directly by α-secretase followed by γ-secretase, a process that does not generate Aβ, or APP can be reinternalized in clathrin-coated pits into another endosomal compartment containing the proteases BACE1 and γ-secretase resulting in the production of Aβ. FRET analysis indicates that γ-secretase activity is present on the cell surface, where it complements α-secretase activity, and in endosomal compartments, where it complements BACE1 activity.<ref name= "o'brien" /> The cleavage of various substrates appears to be dependent on the subcellular compartment; APP is mainly cleaved in the TGN and early endosomal domains thus, a disturbance in the localization of the γ-secretase complex may play some role in abnormal Aβ generation and AD pathogenesis.<ref name= "thompson" />
On the cell surface, amyloid precursor protein (APP) can be proteolyzed directly by α-secretase followed by γ-secretase, a process that does not generate Aβ, or APP can be reinternalized in clathrin-coated pits into another endosomal compartment containing the proteases BACE1 and γ-secretase resulting in the production of Aβ. FRET analysis indicates that γ-secretase activity is present on the cell surface, where it complements α-secretase activity, and in endosomal compartments, where it complements BACE1 activity.<ref name= "o'brien" /> The cleavage of various substrates appears to be dependent on the subcellular compartment; APP is mainly cleaved in the TGN and early endosomal domains thus, a disturbance in the localization of the γ-secretase complex may play some role in abnormal Aβ generation and AD pathogenesis.<ref name= "thompson" />
-
The initial cleavage of APP by α- or β-secretase, results in membrane-bound C-terminal fragments of APP (APP αCTF and βCTF). αCTF and βCTF are further cleaved by γ-secretase to generate p83 or , respectively. The p83 fragment is rapidly degraded and widely believed to have a negligible function, whereas <scene name='81/812869/Matilda_scene_8/5'>Aβ</scene> is neurotoxic.<ref name= "zhang" /> γ-secretase-mediated cleavage is unique in that the cleavage takes place within the transmembrane domain, though the exact site can vary. γ-cleavage can yield both Aβ40, the majority species, and Aβ42, the more amyloidogenic species, as well as release the intracellular domain of APP (AICD). Recent data has shown that PS/γ-secretase also mediates ζ-site cleavage (Aβ46) and ε-site cleavage (Aβ49)<ref name= "thompson" />; the existence of different Aβ species, including the shorter Aβ38 fragments suggests that γ-secretase cleaves APP in a sequential manner, first at the ε-site, followed by the ζ-site, and the γ-site.2 Upon Aβ formation, Aβ is then dumped into the extracellular space following vesicle recycling or degraded in lysosomes.<ref name= "o'brien" />
+
The initial cleavage of APP by α- or β-secretase, results in membrane-bound C-terminal fragments of APP (APP αCTF and βCTF). If γ-secretase cleaves αCTF then p83 is formed, however, if γ-secretase cleaves βCTF is generated. The p83 fragment is rapidly degraded and widely believed to have a negligible function, whereas <scene name='81/812869/Matilda_scene_8/5'>Aβ</scene> is neurotoxic.<ref name= "zhang" /> γ-secretase-mediated cleavage is unique in that the cleavage takes place within the transmembrane domain, though the exact site can vary. γ-cleavage yields Aβ40 and Aβ42 which is the more amyloidogenic species; in addition, it may release intracellular domain of APP (AICD). Recent data has shown that PS/γ-secretase also mediates ζ-site cleavage (Aβ46) and ε-site cleavage (Aβ49)<ref name= "thompson" />; the existence of different Aβ species, including the shorter Aβ38 fragments suggests that γ-secretase cleaves APP in a sequential manner, first at the ε-site, followed by the ζ-site, and the γ-site.2 Upon Aβ formation, Aβ is then dumped into the extracellular space following vesicle recycling or degraded in lysosomes.<ref name= "o'brien" />
== Alzheimer's Disease ==
== Alzheimer's Disease ==
-
Although the majority of Aβ is secreted out of the cell, Aβ can be generated in several subcellular compartments within the cell, such as the ER, Golgi/TGN, and endosome/lysosome. In addition, extracellular Aβ can be internalized by the cell for degradation. The intracellular existence of Aβ implies that Aβ may accumulate within neurons and contribute to disease pathogenesis. Confirming this, intraneuronal Aβ immunoreactivity has been found in the hippocampal and entorhinal cortical regions which are prone to early AD pathology in patients with mild cognitive impairment. In Down Syndrome (DS) patients, the accumulation of intracellular precedes extracellular plaque formation and the level of intraneuronal Aβ decreases as the extracellular Aβ plaques accumulate. Intraneuronal Aβ can also impair amygdala-dependent emotional responses by affecting the ERK/MAPK signaling pathway. Inhibition of dynamin-mediated but not clathrin-mediated Aβ internalization was also found to reduce Aβ-induced neurotoxicity. One recent study suggests that internalized Aβ can aggregate within the cell and disrupt the vesicular membrane, thus contributing to its pathological effect. There are two main toxic species, Aβ40 and Aβ42, with Aβ42 more hydrophobic and more prone to fibril formation while only making up about 10% of the Aβ peptide produced. Studies done on familial AD (FAD) mutations consistently show increases in the ratio of Aβ42/40, suggesting that elevated levels of Aβ42 relative to Aβ40 is critical for AD pathogenesis, probably by providing the core for Aβ assembly into oligomers, fibrils, and amyloidogenic plaques.<ref name="thompson" /> In addition to generating Aβ, γ-secretase cleavage of APP also generates an APP intracellular domain (AICD) within the cell. AICD has been found to possess transcriptional transactivation activity and can regulate the transcription of multiple genes including APP, GSK-3b, KAI1, neprilysin, BACE1, p53, EGFR, and LRP1. In addition, free AICD can induce apoptosis and may play a role in sensitizing neurons to toxic stimuli. <ref name= "zhang" /> However, as the intracellular domain of APP, one important function of AICD is to facilitate the interaction of APP with various cytosolic factors that regulate APP's intracellular trafficking and/or signal transduction function. Interestingly, it seems that AICD-mediated APP interaction with different factors is controlled by the phosphorylation state of AICD.<ref name="thompson" />
+
Although the majority of Aβ is secreted out of the cell, Aβ can be generated in several subcellular compartments within the cell, such as the ER, Golgi/TGN, and endosome/lysosome. The extracellular Aβ is degraded while the intracellular Aβ may accumulate within neurons and contribute to the Alzheimer's Disease. Patients that exhibit mild cognitive impairment are more prone to developing Alzheimer's Disease if they are found to contain intraneuronal Aβ immunoreactivity in the hippocampal and entorhinal cortical regions. Another effect of Aβ aggregation within the cell is disruption of the vesicular membrane leading to its pathological effect. Studies done on familial AD (FAD) mutations consistently show increases in the ratio of Aβ42/40, suggesting that elevated levels of Aβ42 relative to Aβ40 is critical for AD pathogenesis, probably by providing the core for Aβ assembly into oligomers, fibrils, and amyloidogenic plaques.<ref name="thompson" /> In addition to generating Aβ, γ-secretase cleavage of APP also generates an APP intracellular domain (AICD) within the cell. AICD has been found to possess transcriptional transactivation activity and can regulate the transcription of multiple genes including APP, GSK-3b, KAI1, neprilysin, BACE1, p53, EGFR, and LRP1. "In addition, free AICD can induce apoptosis and may play a role in sensitizing neurons to toxic stimuli." <ref name= "zhang" /> However, as the intracellular domain of APP, one important function of AICD is to facilitate the interaction of APP with various cytosolic factors that regulate APP's intracellular trafficking and/or signal transduction function. Interestingly, it seems that AICD-mediated APP interaction with different factors is controlled by the phosphorylation state of AICD.<ref name="thompson" />
== Relevance ==
== Relevance ==
-
There are 32 APP, 179 PSEN1 (presenilin 1 gene locus), and 14 PSEN2 gene mutations that result in early-onset, autosomal dominant, fully penetrant AD. In APP, mutations cluster around the γ-secretase cleavage site, although the most famous APP mutation (APP-swe) causes a change in amino acids adjacent to the BACE1 cleavage site.<ref name= "o'brien" /> AD-related loci are found on chromosome 1 and chromosome 14; two homologous genes, PSEN1(encoding PS1) on chromosome 14 and PSEN2 (encoding PS2) on chromosome 1.2 PSEN gene mutations (which gives rise to proteins presenilin, PS1 and PS2) predominantly alter the amino acids in their nine transmembrane domains. The common thread to all these mutations is that they increase production of the less soluble and more toxic Aβ42 relative to Aβ40.5 Mutations in the PSEN1 gene, encoding presenilin-1 (PS1), are the most common cause of familial Alzheimer’s disease (FAD). <ref>DOI: 10.1073/pnas.1619574114</ref> These familial mutations lead to the heritable form of Alzheimer’s disease.<ref name= "carroll" />
+
There are 32 APP, 179 PSEN1 (presenilin 1 gene locus), and 14 PSEN2 gene mutations that result in early-onset, autosomal dominant, fully penetrant AD. In APP, mutations cluster around the γ-secretase cleavage site, although the most famous APP mutation (APP-swe) causes a change in amino acids adjacent to the BACE1 cleavage site.<ref name= "o'brien" /> AD-related loci are found on chromosome 1 and chromosome 14; two homologous genes, PSEN1(encoding PS1) on chromosome 14 and PSEN2 (encoding PS2) on chromosome 1.<ref name= "zhang" /> PSEN gene mutations (which gives rise to proteins presenilin, PS1 and PS2) predominantly alter the amino acids in their nine transmembrane domains. The common thread to all these mutations is that they increase production of the less soluble and more toxic Aβ42 relative to Aβ40.5 Mutations in the PSEN1 gene are the most common cause of familial Alzheimer’s disease (FAD). <ref>DOI: 10.1073/pnas.1619574114</ref> These familial mutations lead to the heritable form of Alzheimer’s disease.<ref name= "carroll" />
== Structural highlights ==
== Structural highlights ==
-
The structural information of the γ-secretase complex has been primarily obtained by electron microscopy analysis with a maximum resolution of 12 Å, revealing a <scene name='81/812869/Matilda_scene_5/2'>globular structure</scene> with several extracellular domains, three <scene name='81/812869/Matilda_scene_5/3'>polar</scene> cavities, and a potential substrate-binding surface groove in the TM region. Recently a three-dimensional structure of the intact human γ-secretase complex was determined by cryo-electron microscopy with a resolution of 4.5 Å. The overall structural model comprises a horseshoe-shaped structure with 19 TMs and a bilobed ectodomain representing Nicastrin. The extracellular domain of Nicastrin contains a large lobe and a small lobe. The large lobe of Nicastrin thought to be responsible for substrate recognition, associates with the small lobe through a <scene name='81/812869/Matilda_scene_6/1'>hydrophobic pivot</scene> at the center. The current speculative model suggests that PS1 and PEN-2 are located to the “thick” end of the horseshoe shape, whereas APH-1 and Nicastrin are located toward the “thin” end. PEN-2 spans the membrane twice, with N- and C-terminal domains facing the lumen of the ER. Analysis of the APH-1 sequence shows that it contains seven potential TM domains, with the N-terminal domain facing the extracellular space and the C-terminal domain facing the cytosol. Further work is required to elucidate structural details of other γ-secretase components at the atomic level.2 However, strong evidence suggests that the γ-secretase complex resides primarily in the ER, Golgi/TGN, endocytic and intermediate compartments, most of which (except the TGN) are not major subcellular localizations for APP.<ref name="thompson" />
+
The structural information of the γ-secretase complex has been primarily obtained by electron microscopy analysis with a maximum resolution of 12 Å, revealing a <scene name='81/812869/Matilda_scene_5/2'>globular structure</scene> with several extracellular domains, three <scene name='81/812869/Matilda_scene_5/3'>polar</scene> cavities, and a potential substrate-binding surface groove in the TM region. The most recent sturcutre of the γ-secretase complex was visualized by a cryo-electron microscopy with a resolution of 4.5 Å. γ-secretase exhibits a horseshoe-shaped structure with 19 TMs and a bilobed ectodomain which is Nicastrin, "the extracellular domain of Nicastrin contains a large lobe and a small lobe." The large lobe of Nicastrin thought to be responsible for substrate recognition, associates with the small lobe through a <scene name='81/812869/Matilda_scene_6/1'>hydrophobic pivot</scene> at the center. The horseshoe shape is described as having a "thick" end, where PS1 and PEN-2 are located, and "thin" end, where APH-1 and Nicastrin are located. At the thick end, PEN-2 spans the membrane twice as its N- and C-terminal domains face the lumen of the ER. However, at the thin end, APH-1 contains seven TM domains with the N-terminal domain facing the extracellular space and the C-terminal domain facing the cytosol. Further work is required to elucidate structural details of other γ-secretase components at the atomic level.2 However, strong evidence suggests that the γ-secretase complex resides primarily in the ER, Golgi/TGN, endocytic and intermediate compartments, most of which (except the TGN) are not major subcellular localizations for APP.<ref name="thompson" />
This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.
This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.

Revision as of 18:40, 3 May 2019

Gamma Secretase Interaction In Alzheimer's Disease

is a multi-subunit protease complex which cleaves many transmembrane proteins; it is known as an intramembrane protease. γ-secretase is highly studied in its cleavage of amyloid precursor protein (APP) releasing beta-amyloid (Aβ peptides) which further oligomerize to form neurofibrillary tangles and plaques in Alzheimer’s disease.[1]

Gamma Secretase Complex

Drag the structure with the mouse to rotate

References

  1. 1.0 1.1 doi: https://dx.doi.org/10.1016/B978-012351830-9/50024-X
  2. Hanson, R. M., Prilusky, J., Renjian, Z., Nakane, T. and Sussman, J. L. (2013), JSmol and the Next-Generation Web-Based Representation of 3D Molecular Structure as Applied to Proteopedia. Isr. J. Chem., 53:207-216. doi:http://dx.doi.org/10.1002/ijch.201300024
  3. Herraez A. Biomolecules in the computer: Jmol to the rescue. Biochem Mol Biol Educ. 2006 Jul;34(4):255-61. doi: 10.1002/bmb.2006.494034042644. PMID:21638687 doi:10.1002/bmb.2006.494034042644
  4. 4.0 4.1 4.2 4.3 4.4 4.5 4.6 4.7 Zhang X, Li Y, Xu H, Zhang YW. The gamma-secretase complex: from structure to function. Front Cell Neurosci. 2014 Dec 11;8:427. doi: 10.3389/fncel.2014.00427., eCollection 2014. PMID:25565961 doi:http://dx.doi.org/10.3389/fncel.2014.00427
  5. 5.0 5.1 5.2 5.3 5.4 Carroll CM, Li YM. Physiological and pathological roles of the gamma-secretase complex. Brain Res Bull. 2016 Sep;126(Pt 2):199-206. doi:, 10.1016/j.brainresbull.2016.04.019. Epub 2016 Apr 28. PMID:27133790 doi:http://dx.doi.org/10.1016/j.brainresbull.2016.04.019
  6. 6.0 6.1 6.2 6.3 6.4 6.5 Zhang YW, Thompson R, Zhang H, Xu H. APP processing in Alzheimer's disease. Mol Brain. 2011 Jan 7;4:3. doi: 10.1186/1756-6606-4-3. PMID:21214928 doi:http://dx.doi.org/10.1186/1756-6606-4-3
  7. 7.0 7.1 7.2 7.3 7.4 7.5 O'Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer's disease. Annu Rev Neurosci. 2011;34:185-204. doi: 10.1146/annurev-neuro-061010-113613. PMID:21456963 doi:http://dx.doi.org/10.1146/annurev-neuro-061010-113613
  8. Kelleher RJ 3rd, Shen J. Presenilin-1 mutations and Alzheimer's disease. Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):629-631. doi:, 10.1073/pnas.1619574114. Epub 2017 Jan 12. PMID:28082723 doi:http://dx.doi.org/10.1073/pnas.1619574114
Personal tools